Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

Core Insights - Basilea Pharmaceutica Ltd announced a USD 30 million sales milestone payment triggered by strong sales performance of its antifungal drug Cresemba in Europe [1][2] - Cresemba's global in-market sales reached USD 652 million from July 2024 to June 2025, reflecting a 27% year-on-year growth [2] Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, headquartered in Switzerland, focused on developing innovative drugs for severe bacterial and fungal infections [4] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [4] Product Information - Cresemba (isavuconazole) is an intravenous and oral azole antifungal approved in over 70 countries, including the US and most EU member states [2][3] - It is indicated for the treatment of invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate [3]